IL-7 is known to enhance the proliferation and survival of T cells, and co-expression of IL-7 improves NKG2D-based CAR T cells therapy on prostate cancer by enhancing the expansion, inhibiting cell apoptosis and exhaustion [46]. The gene discussed is IL7; the disease is prostate carcinoma.